Effect of Moxifloxacin Combined with Ceftriaxone on Inflammatory Factors and Pulmonary Function in Elderly Patients with Pneumonia

doi:10.16458/j.cnki.1007-0893.2025.18.019

Abstract：Objective: To investigate the therapeutic effect of moxifloxacin combined with ceftriaxone in elderly patients with pneumonia. Methods: A total of 86 elderly patients with pneumonia admitted to Jinsui District General Hospital, Zhengzhou from July 2022 to March 2025 were selected as the study subjects and randomly divided into a control group and an experimental group, each with 43 cases. The control group received ceftriaxone treatment, while the experimental group received moxifloxacin combined with ceftriaxone on the basis of the control group. The therapeutic effects, inflammatory indicators before and after treatment, pulmonary function, and incidence of adverse reactions were compared between the two groups. Results: The total effective rate of treatment in the experimental group was higher than that in the control group, with a statistically significant difference (P < 0.05). After treatment, the levels of white blood cell count (WBC), serum interleukin-6 (IL-6), procalcitonin (PCT), and high-sensitivity C-reactive protein (hs-CRP) in the experimental group were lower than those in the control group, with statistically significant differences (P < 0.05). After treatment, the forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and FEV1/FVC ratio in the experimental group were higher than those in the control group, with statistically significant differences (P < 0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the two groups (P > 0.05). Conclusion: The combination of moxifloxacin and ceftriaxone shows significant therapeutic effects in elderly patients with pneumonia, which is beneficial for inhibiting the body's inflammatory response and improving pulmonary function. Moreover, this treatment regimen has good overall tolerance and fewer adverse reactions.